Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $2.3 million.

  • Northwest Biotherapeutics' Prepaid Assets rose 328.45% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 328.45%. This contributed to the annual value of $1.9 million for FY2024, which is 560.28% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Prepaid Assets stood at $2.3 million, which was up 328.45% from $1.8 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Prepaid Assets' 5-year high stood at $5.7 million during Q1 2021, with a 5-year trough of $1.7 million in Q3 2023.
  • For the 5-year period, Northwest Biotherapeutics' Prepaid Assets averaged around $2.6 million, with its median value being $2.3 million (2025).
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' Prepaid Assets was 10296.2% (2021), while the steepest drop was 6163.17% (2021).
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Prepaid Assets stood at $2.1 million in 2021, then grew by 15.98% to $2.5 million in 2022, then fell by 18.74% to $2.0 million in 2023, then dropped by 5.6% to $1.9 million in 2024, then increased by 23.32% to $2.3 million in 2025.
  • Its Prepaid Assets was $2.3 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.9 million in Q1 2025.